DOAJ Open Access 2025

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

Huijian Zheng Huajian Xian Wenjie Zhang Chaoqun Lu Renyao Pan +2 lainnya

Abstrak

Abstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in MM. We have summarized the latest reports on the three types of drugs for MM at the 2024 ASH Annual Meeting.

Topik & Kata Kunci

Diseases of the blood and blood-forming organs Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Penulis (7)

Huijian Zheng

Huajian Xian

Wenjie Zhang

Chaoqun Lu

Renyao Pan

Han Liu

Zhenshu Xu

Format Sitasi

APA MLA BibTeX

Zheng, H., Xian, H., Zhang, W., Lu, C., Pan, R., Liu, H. et al. (2025). BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting. https://doi.org/10.1186/s13045-025-01675-5

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.1186/s13045-025-01675-5

Informasi Jurnal

Tahun Terbit: 2025
Sumber Database: DOAJ
DOI: 10.1186/s13045-025-01675-5
Akses: Open Access ✓